Daina Graybosch
Stock Analyst at Leerink Partners
(1.31)
# 3,668
Out of 5,149 analysts
99
Total ratings
42.65%
Success rate
-6.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $114.05 | +0.83% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.28 | -12.28% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.58 | +26.58% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.53 | +278.93% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.97 | +135.69% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $15.11 | -20.58% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $119.83 | -0.69% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.44 | +350.45% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $68.11 | -33.93% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.37 | +629.93% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $22.43 | +69.42% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.93 | +62.12% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $100.76 | +122.31% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.57 | +1,067.32% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.59 | +2,805.49% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.00 | +350.00% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $114.05
Upside: +0.83%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.28
Upside: -12.28%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.58
Upside: +26.58%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.53
Upside: +278.93%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.97
Upside: +135.69%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $15.11
Upside: -20.58%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $119.83
Upside: -0.69%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.44
Upside: +350.45%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $68.11
Upside: -33.93%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.37
Upside: +629.93%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $22.43
Upside: +69.42%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.93
Upside: +62.12%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $100.76
Upside: +122.31%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.57
Upside: +1,067.32%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.59
Upside: +2,805.49%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.00
Upside: +350.00%